TRX.L

Tissue Regenix Group Plc
Tissue Regenix Group - Extended distribution agreement with Arthrex, Inc.
26th November 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5948N
Tissue Regenix Group PLC
26 November 2024
 

 

Tissue Regenix Group plc

('Tissue Regenix' or the 'Company')

 

CellRight Technologies extends multi-year distribution agreement with Arthrex, Inc.

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that its subsidiary, CellRight Technologies, LLC ("CellRight"), has amended and extended its long-term, multi-year distribution agreement with Arthrex, Inc. ("Arthrex"), a premier innovator of orthopaedic surgical solutions.  

 

CellRight produces industry leading verified osteobiologics (engineered materials that promote healing of fractures and bone defects) for use in orthopaedic, spine and foot and ankle procedures. The multi-year commitment continues to provide surgeons access to verified osteobiologics and advanced surgical instrumentation and techniques to help influence better patient outcomes. Arthrex and CellRight entered a marketing and sales agreement in March 2017 and the amendment extends the term until October 2029 where it will renew for additional periods.

 

Daniel Lee, CEO of Tissue Regenix, commented: "The extension of our long-term distribution agreement will continue to allow physicians and patients access to CellRight's innovative orthobiologics through the Arthrex network. Patient outcomes are positively impacted by orthobiologic products together with the advanced technologies and training from Arthrex. This shared vision is at the core of this strategic partnership."

 

For more information, please contact:

 

Tissue Regenix Group plc

 

Daniel Lee, Chief Executive Officer

David Cocke, Chief Financial Officer

via Walbrook PR

 

Cavendish Capital Markets (Nominated Adviser and Broker)

 

Geoff Nash/Giles Balleny/Edward Whiley

Nigel Birks - Life Science Specialist Sales

Harriet Ward - ECM

Tel: +44 (0) 20 7466 5000

 

Walbrook PR (Financial PR and IR)

 

Tel: +44 (0)20 7933 8780

Alice Woodings / Lianne Applegarth

Tissue Regenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBABJTMTMTTJI]]>
TwitterFacebookLinkedIn